OTCPK:AROAF (New Zealand)
Â
Ordinary Shares
$
0.52
+0.14 (+35.24%)
10:08 PM EST
Business Description
Aroa Biosurgery Ltd
NAICS : 423450
SIC : 5047
ISIN : NZARXE0001S1
Share Class Description:
AROAF: Ordinary SharesTotal Employee Number:
249Description
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.24 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | 0.54 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 7.93 | |||||
Beneish M-Score | -2.61 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.2 | |||||
3-Year EBITDA Growth Rate | 47.7 | |||||
3-Year Book Growth Rate | -4.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 43.36 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 14.99 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 99.9 | |||||
9-Day RSI | 97.43 | |||||
14-Day RSI | 90.75 | |||||
3-1 Month Momentum % | -26.34 | |||||
6-1 Month Momentum % | -16.21 | |||||
12-1 Month Momentum % | 9.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.77 | |||||
Quick Ratio | 4.4 | |||||
Cash Ratio | 1.67 | |||||
Days Inventory | 190.58 | |||||
Days Sales Outstanding | 63.57 | |||||
Days Payable | 98.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.2 | |||||
Shareholder Yield % | 0.14 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 85.53 | |||||
Operating Margin % | -0.6 | |||||
Net Margin % | 4.5 | |||||
EBITDA Margin % | 11.46 | |||||
FCF Margin % | 6.59 | |||||
OCF Margin % | 10.19 | |||||
ROE % | 4.71 | |||||
ROA % | 3.97 | |||||
ROIC % | -0.63 | |||||
3-Year ROIIC % | 75.91 | |||||
ROC (Joel Greenblatt) % | 11.24 | |||||
ROCE % | 6.33 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 49.17 | |||||
Forward PE Ratio | 65 | |||||
PE Ratio without NRI | 49.17 | |||||
Price-to-Owner-Earnings | 49.17 | |||||
PS Ratio | 2.36 | |||||
PB Ratio | 2.46 | |||||
Price-to-Tangible-Book | 3.06 | |||||
Price-to-Free-Cash-Flow | 36.88 | |||||
Price-to-Operating-Cash-Flow | 23.6 | |||||
EV-to-EBIT | 33.79 | |||||
EV-to-Forward-EBIT | 16.44 | |||||
EV-to-EBITDA | 18.88 | |||||
EV-to-Forward-EBITDA | 11.86 | |||||
EV-to-Revenue | 2.16 | |||||
EV-to-Forward-Revenue | 1.92 | |||||
EV-to-FCF | 32.96 | |||||
Price-to-GF-Value | 0.73 | |||||
Price-to-Graham-Number | 2.6 | |||||
| Price-to-Net-Current-Asset-Value | 4.33 | |||||
| Price-to-Net-Cash | 52 | |||||
Earnings Yield (Greenblatt) % | 2.96 | |||||
FCF Yield % | 2.78 |
Aroa Biosurgery Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aroa Biosurgery Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2025 | 2025-05-21 09:00 | 0.35 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2025-05-21 | 0.35 (+0.00%) | ||
| Third quarter earnings conference call for 2025 | 2025-01-30 09:00 | -- | ||
| Third quarter earnings results for 2025 | 2025-01-30 | -- | ||
| Second quarter earnings conference call for 2025 | 2024-11-22 10:00 | -- | ||
| Second quarter earnings results for 2025 | 2024-11-22 | -- | ||
| General meeting for 2024 | 2024-08-02 12:00 | -- | ||
| First quarter earnings conference call for 2025 | 2024-07-31 09:00 | -- | ||
| First quarter earnings results for 2025 | 2024-07-31 | -- |
Show
Entries
Guru Commentaries on OTCPK:AROAF
No articles.
Press Release
Articles on Aroa Biosurgery Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers